Ariad Pharmaceuticals Inc fka ARIA

[Jen_Mal]

Let's see how the frontline data look before making such lofty proclamations!! Also, where's your evidence to say ponatinib is better first-line vs ANY other agent? Plus, why would you start with a drug that could be your possible salvage therapy? We don't even know what sort of secondary resistance or other yet unknown mutations will pop up with ponatinib. While the third- and fourth-line data are impressive, it seems premature (10 months of follow-up) and dangerous to be making such assumptions that the four other approved agents will be left on the curb. Don't drink that Kool-Aid too quick. Good luck with your doubling of share price... It'll be a good one but breaking into this market will be tough.